Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Cancer Vaccines: Aim and Shoot

Published by: BioSeeker Group AB

Published: May. 19, 2008 - 184 Pages


Table of Contents


1 Executive Summary

2 About Cancer Highlights

3 Methodologies

4 Table of Contents

4.1 List of Figures

4.2 List of Tables

5 How to Use this Report

6 Cancer Vaccines Types

7 The Cancer Genome Project and Cancer Vaccine Drug Targets

7.1 Cancer Vaccine Drug Targets Present in the Cancer Gene Census and in the Catalogue of

Somatic Mutations in Cancer

8 Protein Expression Profiles of Cancer Vaccine Drug Targets in Human

8.1 Expression in Normal Tissues and Cancer Tissues

8.2 Expression in Human Cancer Cell Lines and Primary Cells

9 Pathway Analysis of Cancer Vaccine Drugs

10 Protein-Protein Interactions Among Identified Cancer Vaccine Drug Targets

11 Available Biological Structure Data on Cancer Vaccine Drug Targets

12 Drug Target Profiles of Cancer Vaccine Drug Targets in Oncology

12.1.1 Acid phosphatase activity

12.1.2 Carboxypeptidase activity

12.1.3 Catalytic activity

12.1.4 Cell adhesion molecule activity

12.1.5 Chaperone activity

12.1.6 Cofactor binding

12.1.7 Complement activity

12.1.8 Cytokine activity

12.1.9 DNA binding

12.1.10 DNA topoisomerase activity

12.1.11 DNA-directed DNA polymerase activity

12.1.12 Growth factor activity

12.1.13 Hormone activity

12.1.14 Hydrolase activity

12.1.15 Intracellular ligand-gated ion channel activity

12.1.16 Kinase binding

12.1.17 Kinase regulator activity

12.1.18 Metallopeptidase activity

12.1.19 MHC class I receptor activity

12.1.20 Molecular function unknown

12.1.21 Oxidoreductase activity

12.1.22 Peptidase activity

12.1.23 Peptide hormone

12.1.24 Protein binding

12.1.25 Protein serine/threonine kinase activity

12.1.26 Protein-tyrosine kinase activity

12.1.27 Receptor activity

12.1.28 Receptor binding

12.1.29 Receptor signaling complex scaffold activity

12.1.30 RNA-directed DNA polymerase activity

12.1.31 Serine-type peptidase activity

12.1.32 T cell receptor activity

12.1.33 Transcription factor activity

12.1.34 Transmembrane receptor activity

12.1.35 Transmembrane receptor protein tyrosine kinase activity 12.1.36 Transporter activity

12.1.37 Viral Protein

13 The Drug-Protein Interactome of Cancer Vaccines

14 The Progression and Maturity of Cancer Vaccine Drug Target Combinations

14.1 Target Profiles of Cancer Vaccines in Pre-Registration or on the Market

14.2 New Cancer Vaccine Target Combinations in Phase III Clinical Development

14.3 New Cancer Vaccine Target Combinations in Phase II Clinical Development

14.4 New Cancer Vaccine Target Combinations Phase I Clinical Development

14.5 New Cancer Vaccine Target Combinations in Preclinical Development

14.6 Development Profiles of All Identified Cancer VaccineTarget Combinations

15 Cancer Vaccine Drug Target Mix by Cancer Indication

15.1 Anal Dysplasia

15.2 Basal Cell Cancer

15.3 Bladder Cancer

15.4 Bone Cancer

15.5 Brain Cancer

15.6 Breast Cancer

15.7 Cervical Cancer

15.8 Cervical Dysplasia

15.9 Chemotherapy-Induced Bone Marrow Injury

15.9.1 Chemotherapy-Induced Neutropenia

15.10 Colorectal Cancer

15.11 Gastrointestinal Cancer

15.12 Head and Neck Cancer

15.13 Leukemia

15.13.1 Acute Myelogenous Leukemia

15.13.2 Chronic Lymphocytic Leukemia

15.13.3 Chronic Myelogenous Leukemia

15.14 Liver Cancer

15.15 Lung Cancer

15.15.1 Non-Small Cell Lung Cancer

15.15.2 Small Cell Lung Cancer

15.16 Lymphoma

15.16.1 B-Cell Lymphoma

15.16.2 Non-Hodgkin’s Lymphoma

15.16.3 T-Cell Lymphoma

15.17 Myelodysplastic Syndrome

15.18 Myeloma

15.19 Nasopharyngeal Cancer

15.20 Oesophageal Cancer

15.21 Ovarian Cancer

15.22 Pancreatic Cancer

15.23 Prostate Cancer

15.24 Renal Cancer

15.25 Sarcoma

15.26 Skin Cancer

15.26.1 Melanoma

15.27 Thyroid Cancer

16 Cancer Vaccine Drugs and Their Targets by Companies

16.1 Australia

16.2 Canada

16.3 China

16.4 Denmark

16.5 France

16.6 Germany

16.7 India

16.8 Israel

16.9 Italy

16.10 Japan

16.11 Netherlands

16.12 Norway

16.13 South Korea

16.14 Switzerland

16.15 United Kingdom

16.16 USA

16.17 Non-Industrial Bodies

17 Disclaimer

18 Drug Index

19 Company Index

4.1 List of Figures

Figure 1: Distribution of Compound Types Among Cancer Vaccines

Figure 2: Primary Sub-cellular Localization of Drug Targets

Figure 3: Visualization of Protein-Protein Interactions Among Cancer Vaccine Drug Targets

Figure 4: The Vaccine-Protein Interactome of Cancer Vaccines

Figure 5: Direct Head-to-Head Targeting Interactome of Cancer Vaccines

4.2 List of Tables

Table 2: Drug Targets of Cancer Vaccines Present in the Catalogue of Somatic Mutations in Cancer and in the

Cancer Gene Census

Table 3: Available Protein Expression Profiles of Cancer Vaccine Drug Targets

Table 4: Pathway Summary

Table 5: Drug Targets Without any Identified Assigned Pathways

Table 6: Pathway Profile According to BioCarta of Cancer Vaccine Targets

Table 7: Pathway Profile According to KEGG of Cancer Vaccine Targets

Table 8: Cancer Vaccines Targeting Major Singaling Pathways

Table 9: Protein-Protein Interactions Among Cancer Vaccine Drug Targets

Table 10: Number of Available Biological Structures on Cancer Vaccine Targets

Table 11: Overview of Drug Target Profile Themes

Table 12: Vaccine-Protein Target Clusters in the Cancer Vaccine Drug Target Interactome

Table 13: Fall Out in Terms of the Total Number of Drug Target Mixes, Drugs, Developmental Projects, and the

Presence of New Drug Target Mixes by Developmental Stage

Table 14: Target Profiles of Cancer Vaccines in Pre-Registration or on the Market

Table 15: New Cancer Vaccine Drug Target Combinations in Phase III Clinical Development

Table 16: New Cancer Vaccine Target Combinations in Phase II Clinical Development

Table 17 New Cancer Vaccine Target Combinations Phase I Clinical Development

Table 18: New Cancer Vaccine Target Combinations in Preclinical Development

Table 19: Top 5 Pursued Cancer Vaccine Targets

Table 20: The Progression, Maturity and Comptitive Comparison of Cancer Vaccine Target Mixes in

Development

Table 21: Number of Cancer Vaccine Drug Target Mixes Reported by Cancer Indication

Table 22: Locating Your Competitors/Peers - Step 1

Table 23: Locating Your Competitors/Peers - Step 2

Table 24: Drug Targets of Cancer Vaccines for the Treatment of Anal Dysplasia According to the Compound Type

and Developmental Stage of Vaccine

Table 25: Drug Targets of Cancer Vaccines for the Treatment of Basal Cell Cancer According to the Compound

Type and Developmental Stage of Vaccine

Table 26: Drug Targets of Cancer Vaccines for the Treatment of Bladder Cancer According to the Compound

Type and Developmental Stage of Vaccine

Table 27: Drug Targets of Cancer Vaccines for the Treatment of Bone Cancer According to the Compound Type

and Developmental Stage of Vaccine

Table 28: Drug Targets of Cancer Vaccines for the Treatment of Brain Cancer According to the Compound Type

and Developmental Stage of Vaccine

Table 29: Drug Targets of Cancer Vaccines for the Treatment of Breast Cancer According to the Compound Type

and Developmental Stage of Vaccine

Table 30: Drug Targets of Cancer Vaccines for the Treatment of Cervical Cancer According to the Compound

Type and Developmental Stage of Vaccine

Table 31: Drug Targets of Cancer Vaccines for the Treatment of Cervical Dysplasia According to the Compound

Type and Developmental Stage of Vaccine

Table 32: Drug Targets of Cancer Vaccines for the Treatment of Chemotherapy-Induced Bone Marrow Injury

(General) According to the Compound Type and Developmental Stage of Vaccine

Table 33: Drug Targets of Cancer Vaccines for the Treatment of Chemotherapy-Induced Neutropenia According

to the Compound Type and Developmental Stage of Vaccine

Table 34: Drug Targets of Cancer Vaccines for the Treatment of Colorectal Cancer According to the Compound

Type and Developmental Stage of Vaccine

Table 35: Drug Targets of Cancer Vaccines for the Treatment of Gastrointestinal Cancer According to the

Compound Type and Developmental Stage of Vaccine

Table 36: Drug Targets of Cancer Vaccines for the Treatment of Head and Neck Cancer According to the

Compound Type and Developmental Stage of Vaccine

Table 37: Drug Targets of Cancer Vaccines for the Treatment of Leukemia (General) According to the Compound

Type and Developmental Stage of Vaccine

Table 38: Drug Targets of Cancer Vaccines for the Treatment of Acute Myelogenous Leukemia According to the

Compound Type and Developmental Stage of Vaccine

Table 39: Drug Targets of Cancer Vaccines for the Treatment of Chronic Lymphocytic Leukemia According to the

Compound Type and Developmental Stage of Vaccine

Table 40: Drug Targets of Cancer Vaccines for the Treatment of Chronic Myelogenous Leukemia According to

the Compound Type and Developmental Stage of Vaccine

Table 41: Drug Targets of Cancer Vaccines for the Treatment of Liver Cancer According to the Compound Type

and Developmental Stage of Vaccine

Table 42: Drug Targets of Cancer Vaccines for the Treatment of Lung Cancer (General) According to the

Compound Type and Developmental Stage of Vaccine

Table 43: Drug Targets of Cancer Vaccines for the Treatment of Non Small Cell Lung Cancer According to the

Compound Type and Developmental Stage of Vaccine

Table 44 Drug Targets of Cancer Vaccines for the Treatment of Small Cell Lung According to the Compound Type

and Developmental Stage of Vaccine

Table 45: Drug Targets of Cancer Vaccines for the Treatment of Lymphoma (General) According to the

Compound Type and Developmental Stage of Vaccine

Table 46: Drug Targets of Cancer Vaccines for the Treatment of B-Cell Lymphoma According to the Compound

Type and Developmental Stage of Vaccine

Table 47: Drug Targets of Cancer Vaccines for the Treatment of non-Hodgkin’s Lymphoma According to the

Compound Type and Developmental Stage of Vaccine

Table 48: Drug Targets of Cancer Vaccines for the Treatment of T-Cell Lymphoma According to the Compound

Type and Developmental Stage of Vaccine

Table 49: Drug Targets of Cancer Vaccines for the Treatment of Myelodysplastic Syndrome According to the

Compound Type and Developmental Stage of Vaccine

Table 50: Drug Targets of Cancer Vaccines for the Treatment of Myeloma According to the Compound Type and

Developmental Stage of Vaccine

Table 51: Drug Targets of Cancer Vaccines for the Treatment of Nasopharyngeal Cancer According to the

Compound Type and Developmental Stage of Vaccine

Table 52: Drug Targets of Cancer Vaccines for the Treatment of Oesophageal Cancer According to the

Compound Type and Developmental Stage of Vaccine

Table 53: Drug Targets of Cancer Vaccines for the Treatment of Ovarian Cancer According to the Compound

Type and Developmental Stage of Vaccine

Table 54: Drug Targets of Cancer Vaccines for the Treatment of Pancreatic Cancer According to the Compound

Type and Developmental Stage of Vaccine

Table 55: Drug Targets of Cancer Vaccines for the Treatment of Prostate Cancer According to the Compound

Type and Developmental Stage of Vaccine

Table 56: Drug Targets of Cancer Vaccines for the Treatment of Renal Cancer According to the Compound Type

and Developmental Stage of Vaccine

Table 57: Drug Targets of Cancer Vaccines for the Treatment of Sarcoma According to the Compound Type and

Developmental Stage of Vaccine

Table 58: Drug Targets of Cancer Vaccines for the Treatment of Skin Cancer According to the Compound Type

and Developmental Stage of Vaccine

Table 59: Drug Targets of Cancer Vaccines for the Treatment of Melanoma According to the Compound Type

and Developmental Stage of Vaccine

Table 60: Drug Targets of Cancer Vaccines for the Treatment of Thyroid Cancer According to the Compound

Type and Developmental Stage of Vaccine

Table 61: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Australia

Table 62: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Canada

Table 63: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in China

Table 64: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Denmark

Table 65: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in France

Table 66: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Germany

Table 67: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in India

Table 68: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Israel

Table 69: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Italy

Table 70: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Japan

Table 71: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in the Netherlands

Table 72: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Norway

Table 73: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in South Korea

Table 74: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Switzerland

Table 75: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in United Kingdom

Table 76: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in USA

Table 77: Cancer Vaccines with Drug Target Mix and Developmental Projects by Non-Industrial Bodies

Abstract

Executive Summary

This report aims to analyze the current and future potential of cancer vaccines by examining key fundamentals across the entire pipeline of cancer vaccine drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type. For the purposes of this report, BioSeeker is focusing on therapeutic cancer vaccines and as such the commercialized and pipeline prophylactic agents have not been included.

This report is written for you to identify your competition and understand which targeting strategies are at work within cancer vaccine drug development. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversly it may reveal unexpected competition for you.

Drug targets are the critical link between drugs and their role in the treatment of medical disorders. BioSeeker has surveyed cancer vaccines and identified 75 drug targets belonging to 109 drugs. This report, Cancer Vaccine: Aim and Shoot, is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of cancer vaccine drugs.

In the report, BioSeeker reports on 66 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 109 cancer vaccine drugs designed for the treatment of 37 different cancer indications. The highest degree of distinctiveness among cancer vaccine drugs is achieved by sorting each of them according to targeted cancer indication, drug target mix, and drug compound type. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development.

To fuel the scientific and competitive thinking, BioSeeker opens the gate into the presence and relevance of protein-protein interactions between identified targets of cancer vaccine drugs. No less than 64 protein-protein interactions were recognized among and between 41 of the 75 included cancer vaccine drug targets.

Why You Should Own Your Own Copy of this Report:

  • 180+ pages, with almost a hundred different tables and figures. Includes more than 1,000 active links to related resources on the Internet
  • A 109 cancer vaccine drugs analysis, under development by 76 investigators, covering more than 236 developmental projects in cancer
  • 75 unique, in-depth, drug target profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other drug targets, pursued cancer indications, drugs under development, compound types, presence in the Cancer Genome Project etc.
  • A unique drug target combination breakdown of cancer vaccines into tumor type, compound type, and developmental stage
  • Unique drug-protein target and protein-protein of drug targets interactome analysis
  • Pathway profiling of cancer vaccine drug targets
  • Pin-point which competitor drugs’ clinical out-come may have bearing on your own drug development
  • Who are working on sequels to blockbuster drugs?
  • Locate white-spots in the competitive landscape, giving you little or no competition

In all, this report is a serious reference for any professional interested in the development of oncology drug targets and the selection/validation of targeting strategies.



Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008